Fig. 1

The expression of ZCRB1 and its effects on glycolysis and proliferation in GBM. A Western blot assays were used to detect the expression of ZCRB1 protein in non-tumor brain tissues (NBTs), low-grade glioma tissues (LGGTs), and high-grade glioma tissues (HGGTs). Data are presented as the mean ± SD (n = 9, each group). ^***P < 0.001 vs. NBTs group; ^###P < 0.001 vs. LGGTs group by one-way ANOVA. IDVs, integrated density values. B The expression of ZCRB1 protein in normal human astrocyte (NHA) and GBM cell lines (U251 and U373). Data are presented as the mean ± SD (n = 3, each group). ^**P < 0.01 vs. NHA group by one-way ANOVA. C IF assays were used to detect the localization of ZCRB1 protein in U251 and U373 cells. Red, ZCRB1; blue, DAPI nuclear staining. Scale bars, 10 μm. D and E The effects of ZCRB1 on glucose consumption (D) and lactate production (E) in U251 and U373 cells. F Extracellular acidification rate (ECAR) was measured to demonstrate the effects of ZCRB1 on glycolysis in U251 and U373 cells and the glycolysis was calculated. G Cell viability assays were used to detect the effects of ZCRB1 on proliferation in U251 and U373 cells. Data are presented as the mean ± SD (n = 3, each group). ^*P < 0.05, ^**P < 0.01, ^***P < 0.001 vs. OV-ZCRB1-NC group; ^#P < 0.05, ^###P < 0.001 vs. sh-ZCRB1-NC group by one-way ANOVA. H Kaplan–Meier analysis of the relationship of ZCRB1 expression with overall survival and disease-free survival of glioma patients through GEPIA database. I ROC curve of ZCRB1 mRNA expression in glioma cohort of TCGA database